<DOC>
	<DOCNO>NCT00497315</DOCNO>
	<brief_summary>The aim study evaluate multi modality treatment pemetrexed combine cisplatin radiotherapy lead well tumor control and/or good side-effect profile patient locally advanced NSCLC . Patients randomize 3 cycle induction chemotherapy follow concurrent chemoradiotherapy concurrent chemoradiotherapy follow 3 cycle adjuvant combination chemotherapy .</brief_summary>
	<brief_title>Evaluation Pemetrexed Combined With Cisplatin Radiotherapy Unresectable Locally Advanced Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>cytological histological proven NSCLC unresectable stage III NSCLC presence least one measurable lesion ( RECIST criterion ) adequate haematological , renal hepatic function adequate lung function reserve good condition , weight loss &lt; 10 % previous 6 month , life expectancy &gt; 3 month previous chemo radiotherapy NSCLC distant metastasis malignant pleural pericardial effusion second active primary malignancy serious concomitant medical disease interstitial lung disease autoimmune systemic disease potential involvement lung inability interrupt aspirin nonsteroidal antiinflammatory agent 5day period concomitant use amiodarone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Chemoradiation</keyword>
	<keyword>locally advanced NSCLC</keyword>
	<keyword>pemetrexed</keyword>
	<keyword>lung cancer</keyword>
</DOC>